Drugs / RC1416
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06911866 | Oct 2024 → Sep 2025 | asthma | Nanjing RegeneCore Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06067490 | Jun 2023 → May 2024 | — | Nanjing RegeneCore Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07403487 | Mar 2026 → Oct 2027 expected | asthma | Nanjing RegeneCore Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07402551 | Mar 2026 → May 2028 expected | chronic obstructive pulmonary disease | Nanjing RegeneCore Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC1416 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06911866 ↗ |
| Modality | Protein / enzyme biologic | “RC1416 is a bispecific homodimer nanobody .” NCT06067490 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT06067490 ↗ |